Biohaven completes enrollment in pivotal phase 3 study of taldefgrobep alfa in spinal muscular atrophy

- taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin a signaling, two key regulators of muscle mass and adipose tissue - resilient, the pivotal clinical trial in spinal muscular atrophy, was designed to test the efficacy and safety of taldefgrobep alfa as adjunctive therapy to increase muscle in sma patients treated with standard of care nusinersen, risdiplam or onasemnogene abeparvovec-xioi new haven, conn. , sept. 14, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking